CAZZANIGA, MARINA ELENA
CAZZANIGA, MARINA ELENA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
A chemotherapy-free, pathological response-adapted strategy using trastuzumab–pertuzumab and T-DM1 in HER2-positive early breast cancer: the PHERGain-2 study☆
2026 Garrigos, L; Ruiz-Borrego, M; Perez-Garcia, J; Guerrero-Zotano, A; Cortes-Salgado, A; Kuemmel, S; Colleoni, M; Reboredo-Rendo, C; Bermejo, B; Blancas, I; Gavila, J; Fabi, A; Morales, C; Stradella, A; Caranana, V; Martinez-de Duenas, E; Albacar, C; Ballesteros-Cidras, O; Martrat, G; Iacobucci, S; Boix, O; Berenguer-Molins, P; Alcala-Lopez, D; Cortes, J; Llombart-Cussac, A; Garrigos, L; Ruiz-Borrego, M; Perez-Garcia, J; Guerrero-Zotano, A; Cortes-Salgado, A; Kummel, S; Colleoni, M; Reboredo-Rendo, C; Bermejo, B; Blancas, I; Gavila, J; Fabi, A; Morales, C; Stradella, A; Caranana, V; Martinez-de Duenas, E; Albacar, C; Escriva-de-Romani, S; Musolino, A; Galve-Calvo, E; Quiroga, V; Gluz, O; Lopez Gonzalez, A; Ponce-Lorenzo, J; Cazzaniga, M; Fischer, D; Cortez-Castedo, P; Sanchez-Rovira, P; Morales, S; Zamagni, C; Iranzo, V; Collova, E; Santaballa, A; Cavanna, L; Hoffmann, O; Bassam, A; Garcia-Saenz, J; Medina, A; Palka, M; Al-Farhat, Y; Ballesteros-Cidras, O; Martrat, G; Iacobucci, S; Boix, O; Berenguer-Molins, P; Alcala-Lopez, D; Cortes, J; Llombart-Cussac, A
A hypermetabolic pulmonary lesion in a patient with breast cancer
2026 Franco, G; Promi, S; Galbardi, I; Paciocco, G; Allegranza, P; Cangiotti, C; Bono, F; Zanini, U; Pagni, F; Faverio, P; Guerra, L; Cortinovis, D; Cazzaniga, M; Luppi, F
Metronomic (mCHT) vs standard (sCHT) chemotherapy as first-line treatment in HR+/HER2- Metastatic Breast Cancer (MBC) patients following failure of endocrine treatments. The matched control VICTOR-15 study
2026 Cazzaniga, M; Galimberti, S; Pepe, F; Cogliati, V; Sandretti, F; Capici, S
Metronomic 5-Fluorouracil and Vinorelbine Reduce Cancer Stemness and Modulate EZH2/NOTCH-1/STAT3 Signaling in Triple-Negative Breast Cancer Spheroids
2026 Ilari, A; Grassilli, E; Mauri, M; Cazzaniga, M; Capici, S; Lavitrano, M; Cerrito, M
Multiple Endocrinology Immune-Related Adverse Events (irAEs) Related to Pembrolizumab as Neoadjuvant Treatment in Two Cases of TNBC Patients: Case Reports and Literature Review
2026 Ardakani, K; Passarella, G; Lania, A; Clementi, T; Fanti, A; Pepe, F; Capici, S; Cazzaniga, M
Prospective, randomised, placebo-controlled, phase 2 clinical trial assessing the efficacy and safety of oral vancomycin in patients with primary sclerosing cholangitis with/out inflammatory bowel disease in Italy: study protocol of VanC-IT trial
2026 Cristoferi, L; D'Amato, D; Maino, C; Bernasconi, D; Dinelli, M; Malandrin, S; Facciotti, F; Festa, M; Gerussi, A; Rossi, E; Malinverno, F; Tettamanti, P; Cazzaniga, M; Corso, R; Ippolito, D; Galimberti, S; Invernizzi, P; Carbone, M
Risk Factors for Disease Recurrence in Patients with HER2+ Early Breast Cancer and Implications for Therapy: A Narrative Review
2026 Cazzaniga, M; Costa, L; Freyer, G; Gligorov, J; Lindman, H; Wysocki, P; Bartsch, R
Role of ctDNA in Predicting the Outcome of Patients with Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer Treated with First-line Ribociclib and Letrozole: BioItaLEE Trial
2026 Bianchini, G; Malorni, L; Caputo, R; Zambelli, A; Puglisi, F; Bianchi, G; Del Mastro, L; Paris, I; Montemurro, F; Colleoni, M; Allegrini, G; Tamberi, S; Zamagni, C; Cazzaniga, M; Orditura, M; Guarneri, V; Adamo, V; Romagnoli, E; Valerio, M; Cinieri, S; Benelli, M; Callari, M; Valsecchi, D; Castelletti, D; Grasso, D; Fenderico, N; Arpino, G; De Laurentiis, M
Second-line therapies after CDK4/6 inhibitor failure in HR-positive/HER2-negative metastatic breast cancer patients: real-world data from the HERMIONE-13 study
2026 Cazzaniga, M; Cogliati, V; Rossi, E; Paris, I; Borella, F; Moretti, G; Garrone, O; Pistelli, M; Palumbo, R; Ferro, A; Vici, P; De Giorgi, U; Madaro, S; Coltelli, L; Giordano, M; Gambaro, A; Nicoletti, S; Zustovich, F; Landucci, E; Gamucci, T; Pepe, F; Galimberti, S; Capici, S
VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer
2026 Hurvitz, S; Layman, R; Curigliano, G; André, F; Cristofanilli, M; Kim, S; Martínez Rodríguez, J; Nadal, J; Kim, G; Lo, L; Remolina-Bonilla, Y; Rosselli, G; Emile, G; Korbenfeld, E; Puig, J; Wesolowski, R; Martin, M; Ring, A; Han, H; Giordano, A; Mutka, S; Moss, K; Suzuki, S; Sullivan, B; Gorbatchevsky, I; Pistilli, B; VIKTORIA-1 Study, G; Layman, R; Wesolowski, R; Stringer-Reasor, E; Callahan, R; Han, H; Irvin, W; Makhoul, I; Specht, J; Cristofanilli, M; Jabbour-Aida, H; Chan, D; Giordano, A; Parajuli, R; Silber, A; Vankayala, H; Guaqueta, D; Bashir, T; Wulf, G; Alvarez, R; Blau, S; Suga, J; Babu, S; Gillespie-Twardy, A; Hudson, K; Sobol, U; Claudino, W; Osborne, C; Guimaraes, J; Charpentier, D; Sulpher, J; Phillips, C; Egle, D; Wiesholzer, M; Pusch, R; Heibl, S; Nuytemans, L; Duhoux, F; Neven, P; Altintas, S; Isambert, N; Pistilli, B; Meurer, M; Arnedos, M; Tazi, Y; Priou, F; Emile, G; Mundhenke, C; Schmidt, M; Hackenthal, M; Reimer, T; Deryal, M; Tio, J; Cazzaniga, M; Tonini, G; Colleoni, M; Tortora, G; Biganzoli, L; Boggiani, D; Peron, Y; Gonzalez-Haba Martinez, A; Janez, N; Lopez, C; Alonso Romero, J; Santiago, S; Trucco, A; Serrano, C; Khan, S; Ring, A; O'Brien, C; Waters, S; Ring, A; Mauri, D; Rallis, G
A Phase 2, Open Label, Multicenter, Single Arm Trial Evaluating the Activity and Safety of Abemaciclib + Aromatase Inhibitors (AIs) as Second-Line Treatment After First-Line Fulvestrant in Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-Factor-Receptor-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients. Final Results of HERMIONE-7 Trial
2025 Cazzaniga, M; Pepe, F; Rossi, E; Coltelli, L; Beano, A; Valerio, M; Ferro, A; Zustovich, F; Moretti, G; Toniolo, D; Cordani, N; Galimberti, S; Capici, S
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens
2025 Liu, J; Mo, H; Li, Q; Cazzaniga, M; Ma, F
Oral Anticancer Therapies: Addressing Nonadherence in Patients With Breast Cancer
2025 Cazzaniga, M; Huober, J; Tamma, A; Emde, A; Thoele, K; O'Shaughnessy, J
Predictive Factors of Response to Neoadjuvant Chemotherapy (NACT) and Immune Checkpoint Inhibitors in Early-Stage Triple-Negative Breast Cancer Patients (TNBC)
2025 Ardakani, K; Pepe, F; Capici, S; Clementi, T; Cazzaniga, M
Prognostic Biomarkers in Breast Cancer via Multi-Omics Clustering Analysis
2025 Malighetti, F; Villa, M; Villa, A; Pelucchi, S; Aroldi, A; Cortinovis, D; Canova, S; Capici, S; Cazzaniga, M; Mologni, L; Ramazzotti, D; Cordani, N
Survival Outcomes of Luminal Metastatic Breast Cancer Patients According to Changes in Molecular Subtype at Re-Biopsy: Insights from the GIM-13—AMBRA Study
2025 Cazzaniga, M; Pronzato, P; Amoroso, D; Arpino, G; Atzori, F; Beano, A; Biganzoli, L; Bisagni, G; Blasi, L; Capello, C; Chiari, R; D'Alonzo, A; De Laurentiis, M; Denaro, A; Fabi, A; Farci, D; Ferraù, F; Fiorio, E; Gennari, A; Giotta, F; Giovanardi, F; Gregorc, V; Livi, L; Magnolfi, E; Mosconi, A; Palumbo, R; Pugliese, P; Putzu, C; Ricciardi, G; Riccardi, F; Scortichini, L; Spazzapan, S; Tagliaferri, P; Tinari, N; Tonini, G; Vandone, A; Mustacchi, G
Trastuzumab Duocarmazine in Pretreated Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer: An Open-Label, Randomized, Phase III Trial (TULIP)
2025 Turner, N; Saura, C; Aftimos, P; Van Den Tweel, E; Oesterholt, M; Koper, N; Colleoni, M; Kaczmarek, E; Punie, K; Song, X; Armstrong, A; Bianchi, G; Stradella, A; Ladoire, S; Lim, J; Quenel-Tueux, N; Tan, T; Escrivá-De-Romaní, S; O'Shaughnessy, J; Kuip, E; De Vries, E; Menke-Van Der Houven Van Oordt, W; Papadimitriou, K; Denys, H; Jerusalem, G; Borms, M; Duhoux, F; Macpherson, I; Levitt, N; Palmieri, C; Borley, A; Crook, T; Vega Alonso, E; Morales, S; De Romani Muñoz, S; Jerez Gilarranz, Y; Anton, A; Ponce, J; Adamo, B; Cortes Castan, J; Martinez, M; Petit, T; Teixeira, L; Christophe Thery, J; Abadie-Lacourtoisie, S; Lortholary, A; Luporsi, E; Orfeuvre, H; Bonnin, N; Bianchini, G; Piacentini, F; Cognetti, F; Marchetti, P; Maiello, E; Cazzaniga, M; Guarneri, V; Doni, L; Bordonaro, R; Zamagni, C; Biganzoli, L; Thirlwell, M; Joy, A; Taylor, S; Helsten, T; Chaudhry, M; Ali, H; Dakhil, S; Mowat, R; Brufsky, A; Cobleigh, M; Modiano, M; Cairo, M; Meshad, M; Danso, M; Andersen, J; Harroff, A; Owera, R; Favret, A; Pluard, T; Rosenblatt, P; Jain, S; Jensen, J; Jeppesen, N; Wedervang, K; Edlund, P; Lindman, H; Altena, R; Klint, L; Jing Ying, T; Si Jing, J
Vepdegestrant, a PROTAC Estrogen Receptor Degrader, in Advanced Breast Cancer
2025 Campone, M; De Laurentiis, M; Jhaveri, K; Hu, X; Ladoire, S; Patsouris, A; Zamagni, C; Cui, J; Cazzaniga, M; Cil, T; Jerzak, K; Fuentes, C; Yoshinami, T; Rodriguez-Lescure, A; Sezer, A; Fontana, A; Guarneri, V; Molckovsky, A; Mouret-Reynier, M; Demirci, U; Zhang, Y; Valota, O; Lu, D; Martignoni, M; Parameswaran, J; Zhi, X; Hamilton, E
Clinical Outcomes of HER2-Negative Metastatic Breast Cancer Patients in Italy in the Last Decade: Results of the GIM 13-AMBRA Study
2024 Cazzaniga, M; Pronzato, P; Amoroso, D; Bernardo, A; Biganzoli, L; Bisagni, G; Blasi, L; Bria, E; Cognetti, F; Crinò, L; De Laurentiis, M; Del Mastro, L; De Placido, S; Beano, A; Ferraù, F; Foladore, S; Forcignanò, R; Gamucci, T; Garrone, O; Gennari, A; Giordano, M; Giotta, F; Giovanardi, F; Latini, L; Livi, L; Marchetti, P; Mattioli, R; Michelotti, A; Montemurro, F; Putzu, C; Riccardi, F; Ricciardi, G; Romagnoli, E; Sarobba, G; Spazzapan, S; Tagliaferri, P; Tinari, N; Tonini, G; Turletti, A; Verusio, C; Zambelli, A; Mustacchi, G
Corrigendum: Aromatase inhibitors: the journey from the state of the art to clinical open questions(Front. Oncol., (2023), 13, (1249160), 10.3389/fonc.2023.1249160)
2024 Generali, D; Berardi, R; Caruso, M; Cazzaniga, M; Garrone, O; Minchella, I; Paris, I; Pinto, C; De Placido, S